In a deal that could result in $1.2 billion in milestone payments - on top of a $35 million up-front payment - EPIX Pharmaceuticals Inc. signed with GlaxoSmithKline plc to discover, develop and market drugs that target four G-protein-coupled receptors. (BioWorld Today) Read More